Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.
Metcela has raised $13.7M in total funding. The most recent round was Series C. The last funding was announced in June 2022.
Metcela's investors include UTEC - The University of Tokyo Edge Capital Partners, Beyond Next Ventures, Sony, Sony Innovation Fund, KSP.
Metcela is headquartered in Kawasaki, Japan.
Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.
Metcela is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Metcela — Funding & Investors." VCBacked, June 28, 2022, https://www.vcbacked.co/company/metcela. Accessed August 14, 2026.
VCBacked. (2022). Metcela — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/metcela
{{cite web |title=Metcela — Funding & Investors |url=https://www.vcbacked.co/company/metcela |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated